VEGF Expression of Adenocarcinoma Mammae After Oral Administration of Androgrpahis Paniculata Extract
Angiogenesis was needed to fulfill nutrition and oxygen demand for tumor growthh and its metastase. Vascular endothelial growth factor (VEGF) was a potential proangiogenic factor of angiogenesis process. In vitro study of Andrographis paniculata extract showed decreasing tend of VEGF level serum on PC-3 cancer cell line. The aim of this study was to prove the effect of oral administered Andrographis paniculata extract on VEGF expression of adenocarcinoma mammae C3H mice. Twenty four mice was transplanted with adenocarcinoma mammae randomly to four groups. Andrographis paniculata extract at dose 5, 10, and 15 mg/day were given on mice group along 14 days. One group another as a control. VEGF expression were examined use immunohistochemistry staining. Anova test showed difference VEGF expression among reseach groups (p=0,000, r=-0,953). The highest of VEGF expression index 24,8 was found on control group, and the lowest 19,4 was found on group which received 15 mg/day. We concluded that oral administration of Andrographis paniculata extract decreased VEGF expression of adenocarcinoma mamme C3H mice.
2. Charnock-Jones S. Vascular Endothelial Growth Factors (VEGFs), their receptors and their inhibition. Cell transmissions. 2005. 21(1).
3. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocrine Reviews 2004. 25:581-611.
4. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor and its receptor. The FASEB Journal. 1999. 13:9-22.
5. Su JL, Chen PS, Chien MH, Chen PB, Chen YH, Lai CC, Hung MC, Kuo ML. PgP expression and function of the VEGF-C/VEGFR-3
6. endothelial growth factor. Endocrine Review. 1997. 18:4-25.
7. Sukardiman, Rahman A, Ekasari W, Sismindari. Induksi apoptosis senyawa andrographolida dari sambiloto (Andrographis paniculata Ness) terhadap kultur sel kanker. Media Kedokteran Hewan. 2005. 21(3):105-10.
8. Sukardiman, Harjotaruno, Widyawaruyanti A, Sismindari, and Zaini NC. Apoptosis inducing effect of andrographolide on TD-47 Human breast cancer cell line. African Journal Traditional, CAM. 2007. 4(3):345-51.
9. Nugrahaningsih, Tjahjono, Dharmana E. Apoptosis sel adenokarsinoma mamma mencit C3H setelah pemberian ekstrak sambiloto ( Andrographis paniculata) (Penelitian In Vitro). Media Medika Indonesiana. 2003. 38(3):121-4.
10. Zhao F, He EQ, Wang L, Liu K. Anti-tumor activities of andrographolide, a diterpene from Andrographis paniculata, by inducing apoptosis and inhibiting VEGF level. Journal of Asian Natural Products Research. 2008. 10(5):473-9.
11. Sh e e j a K, Guruv a yoora p pa n C, Kut t a n G. Antiangiogenic activity of Andrographis paniculata extract and andrographolide. International Immunopharmacology. 2007. 7:211-21.
12. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in rerfactoriness/resistance to anti-angiogenic therapies. Drug Resistance Updates. 2008. 11:219-30.
13. Al-Dissi AN, Haines DM, Singh B, Kidney BA. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammay gland adenocarcinoma. Can Vet Journal. 2010. 51:1109-14.
14. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol. 2004. 381:335-54. 15. Semenza GL. HIF-1: Upstream and downstream of cancer metabolism. Current Opinion in Genetic & Development. 2010. 20:51-6. 16. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2(neu) signaling increases the rate of hipoxia-inducible factor 1 alpha (HIF-1 alpha) synthetic: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001. 21:3995-4004.
17. Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000. 60:2898-905.
18. Yoshiji H, Gomez DE, Shibuya M, et al. Expression of vascular endthelial growth factor, its receptor, and other angiogenic factor in human breast cancer. Cancer Res. 1999. 56:2013-6.
19. Safwat, Habib F, Elayat A, Oweiss N, Reffat S, Algaidi S. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinomas of the human breast. Folia Morphol. 2009. 68(3):144–55.
20. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Ling Fu L, Malik AK, Gerber HP, Ferrara N, and Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. The Journal Of Biological Chemistry. 2006. 281(2):951– 61.
21. Fukumura D, Xavier R, Sugiura T, Chen Y , Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998. 94:715-25.
22. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000. 60:6253-8.
23. Kishimoto J, Ehama R, Ge Y , Kobayashi T, Nishiyama T, Detmar M, Burgeson RE. In Vivo detection of human vascula endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol. 2000. 157:103-10.
24. Hakim L. Farmakokinetik Klinik. Yogyakarta: Bursa Ilmu; 2012.
25. Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Concise review: Clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist. 2007. 12:927–41.
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
copy and redistribute the article in any medium or format
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
- NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.